Phase 4 N=280 Immunomodulation Following Transfusion
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=34 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
Hepatitis C
Primary: sCD14 (ng/mL) — 1986; 1918; 1542; 2060 ng/mL — p=0.07
N/A N=12 The Differential Effects of 3 Different Immunosuppressive
Immunosuppression · Kidney Transplantation
Primary: CD4+CD25 High FOXP3+ Cell Levels in Mixed Lymphocyte Reactions (MLRs) of Renal Pre-transplant Recipients/Donors — 90; 85; 25; 50 Percentage of Control Cells
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
Phase 2 N=31 Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Participants With an Average Increase in ALSFRS-R Score of One Point Per Month — 0 Participants
Phase 2 N=70 Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
HIV Infections
Primary: Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12 — -2.0; -0.5; -3.1; -1.2 percent of CD8 expressing HLA-DR+/CD38+ — p=0.428
Phase 2 N=6 Immune Tolerance Study With Aldurazyme® (Laronidase)
Mucopolysaccharidosis I
Primary: Number of Participants Who Achieved Immune Tolerance Induction — 0; 1 participants
Phase 2 N=24 A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System
HIV Infection · Gastrointestinal Symptoms
Primary: Effects of Daily Consumption of GanedenBC30 on Immune Function and Gastro-intestinal Issues
N/A N=133 Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement
Infections After Lung Transplant
Primary: The Primary Outcome Will be the Total Number of Days With Pneumonia. — 1714; 51 Number of days
Phase 3 N=1,971 Immune Modulators for Treating COVID-19
Covid19
Primary: Number of Participants Who Had Recovered by Day 28 — 421; 405; 414; 397 Participants — p=0.0793
Phase 2 N=5 ACTIMMUNE in Intermediate Osteopetrosis
Osteopetrosis
Primary: Number of Participants With Treatment Related Adverse Events CTCAE v4.0 Grade 3 or Higher — 0 Participants
Phase 4 N=33 Mesalamine to Reduce T Cell Activation in HIV Infection
HIV Infections · Sexually Transmitted Diseases · Immune System Diseases
Primary: Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study — 0.03; -0.01 Log10(percentage of T cells) — p=0.63
Phase 4 N=20 The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination
Influenza
Primary: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer — 23; 56.5; 188; 108 HAI antibody Titers
Phase 2 N=76 Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
HIV-1 Infection
Primary: Change in CD8+ T-cell Activation From Baseline to Week 14/16 — 3.24; 0.52 percentage of cells — p=0.030
N/A N=50 Effect of Birth on Immunological Parameters in Cord Blood
Immunologic Activity Alteration
Primary: Cytokines Profile in Cord Blood Plasma — 1.6; 21.81; 165; 14 pg/ml
N/A N=18 Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
HIV Infections
Primary: Change in CSF Concentrations of Neopterin After 12 Weeks — 0.1; 0.3 nmol/L
Phase 2 N=36 Effect of Intralymphatic Immunotherapy
Allergy · Immune Tolerance · Injection Site Discomfort
Primary: Change in cSMS (Combined Symptom and Medication Score) — 2.6; 2.3; 4.5 score on a scale
Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
N/A N=6 Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
Non-small Cell Lung Cancer Stage I
Primary: Examine the T-cell Receptor Profile Changes Induced in the Tumor After SABR
Early Phase 1 N=12 Ivermectin and Human Immunity
Ivermectin
Primary: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded. — 0; 0; 0; 0 Cytokines changed from t=0
Phase 2 N=34 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Tick Borne Encephalitis
Primary: Outcome of the Neutralization Test (Number of Subjects With Antibody Response Measured by Neutralization Assay) — 6; 14 Participants — p=<0.001
N/A N=20 Immunologic Effects of Echinacea
Upper Respiratory Tract Infections
Primary: Maximal Level of Tumor Necrosis Factor Alpha (pg/ml) — 2694; 2648 tumor necrosis alpha level (pg/ml) — p=.17
Phase 1 N=89 Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants
Focus: Nutritional Requirements for Infants
Primary: Number of Antigen-presenting B Cells — 21.9; 22.8; 25.1 percentage of CD20+ B cells
Phase 2 N=40 Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria — 15.8; 20.0 percentage of participants
N/A N=16 Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge
Celiac Disease
Primary: Change From Baseline in Small Intestine Histology Based on Villous Height to Crypt Depth (Vh:Cd) Ratio — 2.10; 2.30; -0.06; -1.53 ratio — p=0.385
Phase 2 N=25 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48
Phase 4 N=15 Immunologic Response to Secukinumab in Plaque Psoriasis
Psoriasis
Primary: Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline — -1.42 percent change from week 0
Phase 4 N=17 Immune Monitoring to Facilitate Belatacept Monotherapy
Kidney Transplant Rejection · Immunosuppression
Primary: Incidence of Acute Rejection — 0 Participants
N/A N=133 Selenium and Immune Function
Healthy
Primary: Cellular and Humoral Immune Response — 0.29; 0.34; 0.34; 0.29 umol/min — p=<0.05